구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD19 CAR-T |
Overview Company | Juventas Cell Therapy Ltd. |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | B-cell Malignancy; B-cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | adenoviral hemorrhagic cystitis as an uncommon complication after CD19 CAR-T cell therapy |
MoA Mechanism | CAR-T cells with increasing amounts of antigen-loaded beads yielded a dose-dependent secretion of IFN-γ, whereas non-loaded or MOCK antigen-loaded beads did n |
MoA Biomarker | CD19 CAR-T cells, cryopreserved CAR-T cells yielded low |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | thrombocytopenia (41 |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia (41 |
Clinical Selected reported efficacy | ORR 88% |
Clinical Reported ORR | 88% |
Clinical Reported PFS | 23.6 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT04002401 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04002401 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD19 CAR-T |
Overview Company | Juventas Cell Therapy Ltd. |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | B-cell Malignancy; B-cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | adenoviral hemorrhagic cystitis as an uncommon complication after CD19 CAR-T cell therapy |
MoA Mechanism | CAR-T cells with increasing amounts of antigen-loaded beads yielded a dose-dependent secretion of IFN-γ, whereas non-loaded or MOCK antigen-loaded beads did n |
MoA Biomarker | CD19 CAR-T cells, cryopreserved CAR-T cells yielded low |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | thrombocytopenia (41 |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia (41 |
Clinical Selected reported efficacy | ORR 88% |
Clinical Reported ORR | 88% |
Clinical Reported PFS | 23.6 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT04002401 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04002401 |
추천 비교
추천 비교